United States: FDA Provides New Product Specific Guidance For Development Of Certain Generic Drug Products

This article summarizes information taken from the following sources: FDA's Draft Guidance for Industry on Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application (ANDA) (Dec. 2013) & information set forth in the following link: https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075207.htm

In order to launch a generic version of an approved reference listed drug ("RLD"), an applicant must file an abbreviated new drug application ("ANDA") generally demonstrating, among other things, that a proposed generic drug product is bioequivalent ("BE") to the RLD.1

The FD&C Act provides that a generic drug is bioequivalent to the RLD if:

The rate and extent of absorption of the drug do not show a significant difference from the rate and extent of absorption of the listed drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses. . .2

For most products, the focus of BE studies is on the release of the drug substance from the drug product into the systemic circulation. During such BE studies, an applicant compares the systemic exposure profile of a test drug product to that of the RLD.

Under FDA regulations, an applicant must use "the most accurate, sensitive, and reproducible approach available among those set forth" in 21 C.F.R. § 320.24(b) to demonstrate BE.3 As noted in 21 C.F.R. § 320.24, in vivo and/or in vitro methods can be used to establish BE. In general descending order of preference, these include pharmacokinetic, pharmacodynamic, clinical, and in vitro studies.4

The statutory definition of BE, expressed in terms of rate and extent of absorption of the active ingredient or moiety, emphasizes the use of pharmacokinetic endpoints in an accessible biological matrix, such as blood, plasma, and/or serum, to indicate release of the drug substance from the drug product into the systemic circulation. BE frequently relies on pharmacokinetic endpoints such as Cmax (peak plasma concentration) and AUC (area under the plasma concentration time curve) that are reflective of rate and extent of absorption, respectively.

If serial measurements of the drug or its metabolites in plasma, serum, or blood cannot be accomplished, measurement of urinary excretion can be used to demonstrate BE.

FDA recommends use of a two-period, two-sequence, two-treatment, single-dose, crossover study design, a single-dose parallel study design, or a replicate study design for BE studies. For most dosage forms that release drug intended to be systemically available, FDA recommends that applicants perform a two-period, two-sequence, two-treatment, single-dose, crossover study using healthy subjects. In this design, each study subject should receive each treatment (test, and RLD) in random order. The crossover design may not be practical for drugs with long pharmacokinetic half-lives (i.e., longer than 24 hours). In such cases, investigators can use a single-dose, parallel design where each treatment should be administered to a separate group of subjects with similar demographics.

A replicate crossover study may be an appropriate alternative to the parallel or non-replicate crossover study described above, and can be conducted as either a partial (three-way) or full (four-way) replication of treatment. In this design, one or both treatments should be administered to the same subject on two separate occasions. The replicate design has the advantage of using fewer subjects although each subject should receive more treatments.

According to 21 C.F.R. § 320.24, different types of evidence may be used to establish bioequivalence for pharmaceutically equivalent drug products, including in vivo or in vitro testing, or both. The selection of the method used to demonstrate bioequivalence depends upon the purpose of the study, the analytical methods available, and the nature of the drug product. Under this regulation, applicants must conduct bioequivalence testing using the most accurate, sensitive, and reproducible approach available among those set forth in 21 C.F.R. § 320.24.

To further facilitate generic drug product availability and to assist the generic pharmaceutical industry with identifying the most appropriate methodology for developing drugs and generating evidence needed to support ANDA approval, FDA publishes product-specific guidances describing the Agency's current thinking and expectations on how to develop generic drug products therapeutically equivalent to specific reference-listed drugs.

These guidances are published in an incremental manner and the most recently published new guidances are listed below in alphabetical order according to RLD's name.

Active Ingredient Route of Administration Dosage Form RLD Application Number
(link to Orange Book)
Azelastine hydrochloride Nasal Spray, metered 022203
Azithromycin Oral Suspension 050693
Barium sulfate Oral Paste 208844
Betamethasone dipropionate Topical Lotion 017781
Budesonide Rectal Aerosol, Foam 205613
Canagliflozin; Metformin Hydrochloride Oral Tablet, Extended Release 205879
Dantrolene sodium Intravenous Suspension 205579
Dapsone Topical Gel 207154
Deflazacort Oral Suspension 208685
Deflazacort Oral Tablet 208684
Docosanol Topical Cream 020941
Empagliflozin; Metformin Hydrochloride Oral Tablet, Extended Release 208658
Epinephrine Intramuscular/Subcutaneous Injectable 020800
Erythromycin Topical Gel 050617
Everolimus Oral Tablet for Suspension 203985
Fluorometholone Ophthalmic Drops, Suspension 016851
Fluticasone propionate inhalation Aerosol, metered 021433
Fluticasone propionate inhalation Powder 020833
Hydrocortisone acetate Rectal Aerosol, Metered 017351
Ivermectin Topical Cream 206255
Levorphanol tartrate Oral Tablet 008720
Lisdexamfetamine dimesylate Oral Tablets, Chewable 208510
Methylphenidate Hydrochloride Oral Tablets, Extended Release 18029
Mometasone furoate Inhalation Powder 021067
Nitisinone Oral Capsule 021232
Olaparib Oral Capsule 206162
Osimertinib mesylate ( Oral Tablets 208065
Permethrin Topical Cream 019855
Pirfenidone Oral Tablet 208780
Salmeterol Xinafoate Inhalation Powder 020692
Telotristat etiprate Oral Tablet 208794
Terbutaline sulfate Oral Tablet 017849
Tiotropium bromide) Inhalation Powder 021395

Seyfarth Shaw will continue to provide updates to the FDA's Product Specific Guidance as well as other updates on generic drugs provided by the FDA.

Footnotes

1 See Section 505(j)(2)(A)(iv) of the FD&C Act; 21 C.F.R. § 314.94(a)(7).

2 Section 505(j)(8)(B)(i) of the FD&C Act. See also section 505(j)(8)(B)(ii), (C) of the FD&C Act; 21 C.F.R. §§ 320.1(e), and 320.23(b).

3 See 21 C.F.R. § 320.24(a).

4 See 21 C.F.R. § 320.24(b).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.